Core Viewpoint - Fosun Pharma (600196.SH) is planning to divest 100% equity of Shanghai Clone to enhance focus on core business and improve asset operation efficiency [1] Group 1: Transaction Details - Fosun Pharma's subsidiary, Fosun Pharma Industry, intends to invest RMB 54.6 million as a limited partner (LP) to establish a special fund with Hongyi Tianjin and Zhonghui Life Insurance, expecting to hold 9.98% of the fund's assets after full fundraising [1] - The subsidiary plans to transfer its 100% equity in Shanghai Clone and related debts to the special fund or its controlled entities for no more than RMB 1.256 billion after the fund is established and conditions are met [1] - Following the transfer, the group will no longer hold equity in Shanghai Clone but will continue to lease part of the property as an operating site, with no significant impact on daily operations expected [1] Group 2: Use of Proceeds - The proceeds from this transfer will be utilized for continued investment in the group's innovative drug business [1]

Core Viewpoint - Fosun Pharma (600196.SH) announced plans to transfer 100% equity of Shanghai Clone, with the proceeds aimed at continuous investment in innovative drug business [1] Group 1: Equity Transfer - Fosun Pharma's subsidiary intends to transfer 100% equity of Shanghai Clone [1] - The transfer is expected to generate proceeds of up to 1.256 billion yuan [1] Group 2: Fund Establishment - Fosun Pharma's subsidiary plans to invest 54.6 million yuan as a limited partner (LP) to establish a special fund with Hongyi Tianjin and Zhonghui Life Insurance [1] - After the establishment of the special fund, Fosun Pharma's subsidiary is expected to hold a 9.98% share of the fund's assets [1]

重要内容提示 ●交易概况： 为进一步聚焦核心业务并提升资产运营效率，控股子公司复星医药产业拟筹 划转让上海克隆 100%股权（其主要资产为位于上海市徐汇区宜山路 1289 号的标 的物业），本次交易步骤及结构如下： 上海复星医药（集团）股份有限公司 关于参与设立私募股权投资基金 及筹划出售资产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600196 股票简称：复星医药 编号：临 2025-151 1、控股子公司复星医药产业拟作为 LP 现金出资人民币 5,460 万元与弘毅天 津、中汇人寿共同出资设立专项基金（即本次投资），预计持有该基金足额募集 后 9.98%的财产份额； 2、于专项基金设立并满足约定条件后，控股子公司复星医药产业拟以不超 过人民币 125,600 万元向专项基金或其控制的实体转让所持有的上海克隆 100% 的股权和对上海克隆享有的债权（即本次转让）。 本次转让完成后，本集团将不再直接持有上海克隆的股权，但仍将继续租赁 部分标的物业作为经营场所，预计本次转让不会对本集团之日常运营造成重大 ...

Core Viewpoint - Fosun Pharma's subsidiary plans to transfer 100% equity and debt of Shanghai Clone for a consideration not exceeding 1.256 billion yuan, aiming to focus on core business and enhance asset operation efficiency [1] Group 1: Transaction Details - The transaction involves a total consideration of up to 1.256 billion yuan [1] - The special fund plans to raise 547 million yuan, with Fosun Pharma contributing 54.6 million yuan, holding a 9.98% share of the fund [1] - After the transaction, Fosun Pharma will no longer hold equity in Shanghai Clone but will continue to lease part of the property for operational purposes [1] Group 2: Strategic Intent - The proceeds from the transfer will be used for continued investment in innovative drug business [1]

Core Viewpoint - Fosun Pharma's subsidiary plans to transfer 100% equity of Shanghai Clone, with the proceeds aimed at further investment in innovative drug business [1] Group 1: Transaction Details - Fosun Pharma's subsidiary, Fosun Pharma Industry, intends to contribute RMB 54.6 million as a limited partner (LP) to establish a special fund with Hongyi Tianjin and Zhonghui Life Insurance [1] - The subsidiary expects to hold a 9.98% share of the fund's assets after full fundraising [1] - The subsidiary plans to transfer its 100% equity in Shanghai Clone and related debts for no more than RMB 1.256 billion to the special fund or its controlled entities [1] Group 2: Operational Impact - Following the transfer, the group will no longer hold direct equity in Shanghai Clone but will continue to lease part of the property as an operational site [1] - The transaction is expected to have no significant impact on the group's daily operations [1] Group 3: Use of Proceeds - Proceeds from the transfer will be utilized for ongoing investments in the group's innovative drug business [1]

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received approval from the National Medical Products Administration for its innovative small molecule CDK4/6 inhibitor, Fovisei (Citrus Acid Vovisil Capsules), for a new indication in the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer in premenopausal, postmenopausal, and perimenopausal women [1][3]. Group 1 - The approval allows Fovisei to be used in combination with aromatase inhibitors as initial endocrine therapy for specific breast cancer patients [1][3]. - Breast cancer is a significant health threat to women, with approximately 357,200 new cases reported in China in 2022, making it the second most common malignant tumor among women [3]. - CDK4/6 inhibitors are crucial treatment options for HR+/HER2- populations with endocrine resistance [3]. Group 2 - Fovisei is classified as a first-class new drug, characterized as an oral, potent, highly selective, and structurally novel small molecule medication [3]. - The drug can penetrate the blood-brain barrier, providing new treatment opportunities for patients with brain metastases [3]. - Taimei Medical Technology, as a partner, played a key role in the independent imaging assessment for the drug's approval, leveraging its extensive experience and quality management systems [3].

Group 1 - The pharmaceutical sector in both A-shares and Hong Kong stocks experienced a collective decline on September 26 [1] - In A-shares, Sunflower dropped by 10%, while Guangsheng Tang and Aosaikang fell over 8%. Other companies like Jimin Health, Hanyu Pharmaceutical, Wanbangde, Hengrui Medicine, and Huiyu Pharmaceutical also saw declines [1] - In Hong Kong stocks, WuXi AppTec decreased by over 5%, BeiGene fell by more than 4%, and Fosun Pharma dropped nearly 2% [1]

Company Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was established on May 31, 1995, and listed on August 7, 1998. The company is primarily engaged in drug manufacturing and research, covering medical devices, medical diagnostics, medical services, and pharmaceutical distribution and retail [1]. Financial Performance - For the first half of 2025, Fosun Pharma reported operating revenue of 19.514 billion yuan, a year-on-year decrease of 4.63%. However, the net profit attributable to shareholders increased by 38.96% to 1.702 billion yuan [2]. - The company has cumulatively distributed 12.593 billion yuan in dividends since its A-share listing, with 2.691 billion yuan distributed over the past three years [3]. Stock Performance - As of September 26, Fosun Pharma's stock price was 29.69 yuan per share, with a market capitalization of 79.285 billion yuan. The stock has increased by 21.02% year-to-date but has seen a decline of 4.01% over the past five trading days [1]. - The stock's trading volume on September 26 was 182 million yuan, with a turnover rate of 0.29% [1]. Shareholder Structure - As of June 30, 2025, Fosun Pharma had 230,000 shareholders, a decrease of 4.37% from the previous period. The average circulating shares per shareholder remained at 0 [2]. - The top circulating shareholder is Hong Kong Central Clearing Limited, holding 75.881 million shares, an increase of 11.194 million shares from the previous period [3].

两融数据显示，该股最新融资余额为25.00亿元，近5日减少9419.10万元，降幅为3.63%。 据天眼查APP显示，上海复星医药(集团)股份有限公司成立于1995年05月31日。注册资本267042.9325万 人民币。（数据宝） 复星医药9月25日大宗交易平台出现一笔成交，成交量60.00万股，成交金额1818.00万元，大宗交易成交 价为30.30元。该笔交易的买方营业部为国泰海通证券股份有限公司总部，卖方营业部为国泰海通证券 股份有限公司郑州黄河路证券营业部。 进一步统计，近3个月内该股累计发生2笔大宗交易，合计成交金额为2698.33万元。 证券时报·数据宝统计显示，复星医药今日收盘价为30.30元，下跌0.13%，日换手率为1.40%，成交额为 9.01亿元，全天主力资金净流出4803.88万元，近5日该股累计下跌4.14%，近5日资金合计净流出2.82亿 元。 | 成交量 （万 | 成交金额 | 成交价 | 相对当日收盘折 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | | （万元） | 格 | 溢价（%） | | | | 股） ...

Group 1 - The core viewpoint of the article highlights the growth in China's chemical pharmaceutical raw material production, with a reported output of 329,000 tons in May 2025, reflecting a year-on-year increase of 3.8% [1] - Cumulative production of chemical pharmaceutical raw materials from January to May 2025 reached 1,585,000 tons, showing a cumulative growth of 5% [1] - The article references a report by Zhiyan Consulting, which provides insights into the market supply and demand trends in the Chinese chemical pharmaceutical industry from 2025 to 2031 [1] Group 2 - The listed companies in the article include Heng Rui Medicine, East China Medicine, Li Zhu Group, Baiyunshan, North China Pharmaceutical, Hai Zheng Pharmaceutical, Fosun Pharmaceutical, Ke Lun Pharmaceutical, En Hua Pharmaceutical, and Xian Ju Pharmaceutical [1] - Zhiyan Consulting is described as a leading industry consulting firm in China, specializing in in-depth industry research reports, business plans, feasibility studies, and customized services [1] - The article emphasizes Zhiyan Consulting's commitment to providing comprehensive industry solutions to empower investment decisions through professional insights and market acumen [1]